EUVIMEDEUVIMED entdecken
Crossref

Budget Impact Analysis of Biosimilar Natalizumab in the US

Edward Li, Adrian Goh, Soni Gupta, Marion Schauf, Anna Chen, Daniel M Hartung

The American Journal of Managed Care · 2024

DOI: 10.37765/ajmc.2024.89558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Journal of Managed Care, 2024. Verfasst von Edward Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sandoz Inc, 100 College Rd W, Princeton, NJ 08540. Email: anna-1.chen@sandoz.com. Hauptthemen laut MEDLINE: Natalizumab, Biosimilar Pharmaceuticals, Budgets. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NatalizumabBiosimilar PharmaceuticalsBudgetsHumansUnited StatesAntibodies, Monoclonal, HumanizedMultiple Sclerosis, Relapsing-RemittingCost-Benefit AnalysisCost SavingsDrug Costs

Substanzen

NatalizumabBiosimilar PharmaceuticalsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Sandoz Inc, 100 College Rd W, Princeton, NJ 08540. Email: anna-1.chen@sandoz.com.

Zitieren

APA

Li, E., Goh, A., Gupta, S., Schauf, M., Chen, A., & Hartung, D. M. (2024). Budget Impact Analysis of Biosimilar Natalizumab in the US. The American Journal of Managed Care. https://doi.org/10.37765/ajmc.2024.89558

Vancouver

Li E, Goh A, Gupta S, Schauf M, Chen A, Hartung DM. Budget Impact Analysis of Biosimilar Natalizumab in the US. The American Journal of Managed Care. 2024. doi:10.37765/ajmc.2024.89558

BibTeX
@article{Li2024,
  author = {Li, Edward and Goh, Adrian and Gupta, Soni and Schauf, Marion and Chen, Anna and Hartung, Daniel M},
  title = {Budget Impact Analysis of Biosimilar Natalizumab in the US},
  journal = {The American Journal of Managed Care},
  year = {2024},
  doi = {10.37765/ajmc.2024.89558}
}
Kostenlos starten →